Aug 2026
Tumor-derived KLK5 activates TMEM158+ cancer-associated fibroblasts to induce CD8+ T cell exhaustion and confer immunotherapy resistance in lung cancer.
AIM Immune checkpoint blockade (ICB) has improved the treatment landscape of lung squamous cell carcinoma (LUSC), but durable clinical benefit is limited by frequent therapeutic resistance. We aimed to define the microenvironmental mechanisms underlying ICB resistance in LUSC. METHODS Surgical specimens from LUSC pat...
Shuangpeng Pu, Guo-Dong Li, Yu-Ran Jiang et al.
· Drug resistance updates · 0 citations